Muthalagu Ramanathan

List of Publications by Year
in descending order

27 papers	840 citations	840776 11 h-index	713466 21 g-index
27 all docs	27 docs citations	27 times ranked	1849 citing authors

#	Article	IF	Citations
1	Bortezomib-Based Induction Is Associated with Superior Outcomes in Light Chain Amyloidosis Patients Treated with Autologous Hematopoietic Cell Transplantation Regardless of Plasma Cell Burden. Transplantation and Cellular Therapy, 2021, 27, 264.e1-264.e7.	1.2	13
2	Validation of an electronic algorithm for Hodgkin and <scp>nonâ€Hodgkin</scp> lymphoma in <scp>ICDâ€10â€CM</scp>. Pharmacoepidemiology and Drug Safety, 2021, 30, 910-917.	1.9	5
3	Impact of pretransplant mutation status on survival after allogeneic stem cell transplant for acute myeloid leukemia. EJHaem, 2021, 2, 514-519.	1.0	0
4	Clinico-genomic profiling and clonal dynamic modeling of TP53-aberrant myelodysplastic syndrome and acute myeloid leukemia. Leukemia and Lymphoma, 2021, 62, 3348-3360.	1.3	11
5	The Incidence and Impact of Clostridioides Difficile Infection (CDI) on Outcomes after Allogeneic Hematopoietic Cell Transplant (alloHCT) - a CIBMTR Study. Blood, 2021, 138, 2894-2894.	1.4	0
6	Treatment of Acute Graft-versus-Host Disease in Liver Transplant Recipients. Case Reports in Transplantation, 2021, 2021, 1-6.	0.3	0
7	Maintenance Tyrosine Kinase Inhibitors Following Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Myelogenous Leukemia: A Center for International Blood and Marrow Transplant Research Study. Biology of Blood and Marrow Transplantation, 2020, 26, 472-479.	2.0	21
8	Elotuzumab-based maintenance therapy following autologous stem cell transplant in multiple myeloma deepens post-transplant responses. Blood Cells, Molecules, and Diseases, 2020, 85, 102482.	1.4	2
9	Elderly do benefit from induction chemotherapy: High dose mitoxantroneâ€based (â€œ5 + 1â€) induction chemotherapy regimen in newly diagnosed acute myeloid leukemia. American Journal of Hematology, 2019, 94, 209-215.	4.1	8
10	Autologous/Allogeneic Hematopoietic Cell Transplantation versus Tandem Autologous Transplantation for Multiple Myeloma: Comparison of Long-Term Postrelapse Survival. Biology of Blood and Marrow Transplantation, 2018, 24, 478-485.	2.0	31
11	High Dose Mitoxantrone Based "5+1" Induction Chemotherapy Regimen in Newly Diagnosed Acute Myeloid Leukemia. Blood, 2018, 132, 1430-1430.	1.4	0
12	Hematopoeitic Cell Transplant - Comorbidity Index (HCT-CI) Score Is a Useful Tool for Predicting Induction Mortality and Overall Survival in Newly Diagnosed Acute Myeloid Leukemia Patients. Blood, 2018, 132, 1396-1396.	1.4	0
13	Outcomes after Umbilical Cord Blood Transplantation for Myelodysplastic Syndromes. Biology of Blood and Marrow Transplantation, 2017, 23, 971-979.	2.0	16
14	Maintenance versus Induction Therapy Choice on Outcomes after Autologous Transplantation for Multiple Myeloma. Biology of Blood and Marrow Transplantation, 2017, 23, 269-277.	2.0	19
15	Metabolic Syndrome and Cardiovascular Disease after Hematopoietic Cell Transplantation: Screening and Preventive Practice Recommendations from the CIBMTR and EBMT. Biology of Blood and Marrow Transplantation, 2016, 22, 1493-1503.	2.0	55
16	Early cytomegalovirus reactivation remains associated with increased transplant-related mortality in the current era: a CIBMTR analysis. Blood, 2016, 127, 2427-2438.	1.4	403
17	Post-Transplant Outcomes in High-Risk Compared with Nonâ€“High-Risk Multiple Myeloma: A CIBMTR Analysis. Biology of Blood and Marrow Transplantation, 2016, 22, 1893-1899.	2.0	34
18	Hematopoietic Cell Transplantation Outcomes in Monosomal Karyotype Myeloid Malignancies. Biology of Blood and Marrow Transplantation, 2016, 22, 248-257.	2.0	33

#	Article	IF	Citations
19	Comparison of Outcomes of Allogeneic Transplantation for Chronic Myeloid Leukemia with Cyclophosphamide in Combination with Intravenous Busulfan, Oral Busulfan, or Total Body Irradiation. Biology of Blood and Marrow Transplantation, 2015, 21, 552-558.	2.0	12
20	Post-Autologous (ASCT) Stem Cell Transplant Therapy in Multiple Myeloma. Advances in Hematology, 2014, 2014, 1-12.	1.0	11
21	Early relapse of Burkitt lymphoma heralded by a bone marrow necrosis and numb chin syndrome successfully treated with allogeneic stem cell transplantation. Leukemia Research Reports, 2014, 3, 51-53.	0.4	3
22	Second Solid Cancers after Allogeneic Hematopoietic Cell Transplantation Using Reduced-Intensity Conditioning. Biology of Blood and Marrow Transplantation, 2014, 20, 1777-1784.	2.0	50
23	Older Patients with Myeloma Derive Similar Benefit from Autologous Transplantation. Biology of Blood and Marrow Transplantation, 2014, 20, 1796-1803.	2.0	73
24	Allotransplantation for Patients Age â‰¥40 Years with Non-Hodgkin Lymphoma: Encouraging Progression-Free Survival. Biology of Blood and Marrow Transplantation, 2014, 20, 960-968.	2.0	37
25	Early CMV Reactivation Still Remains a Cause of Increased Transplant Related Mortality in the Current Era: A CIBMTR Analysis. Blood, 2014, 124, 47-47.	1.4	2
26	Autologous (Auto) Peripheral Blood Stem Cell (SCT) As a Consolidation Therapy for Patients with Acute Myeloid Leukemia (AML) in 1st Complete Remission (CR): A Single Institution Experience. Blood, 2011, 118, 4505-4505.	1.4	0
27	High Complete Remission (CR) Rates and Reduced Early Mortality with High Dose Ara-c (HiDAC) and Mitoxantrone (MITO) Induction Chemotherapy for Older (age>60) High Risk Patients with Acute Myeloid Leukemia (AML). Blood, 2010, 116, 3290-3290.	1.4	1